American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1353)
  10. Hematologic Malignancies, Division of (1281)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2579)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2- breast cancer (BC)
    Meeting Abstract

    Juric, D.; Patel, M. R.; Duska, L. R.; Jhaveri, K. L.; Henick, B. S.; Matulonis, U. A.; Munster, P. N.; Birrer, M. J.; Moore, K. N.; Curigliano, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma
    Meeting Abstract

    Mora, J.; Chan, G. C.; Morgenstern, D. A.; Amoroso, L.; Nysom, K.; Faber, J.; Wingerter, A.; Bear, M.; Rubio-San-SimoĢn, A.; Eldridge, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202
    Meeting Abstract

    Muro, K.; Chin, K.; Maron, S. B.; Braiteh, F. S.; Mitani, S.; Hara, H.; Kuboki, Y.; Mulcahy, M. F.; Baranda, J. C.; Gardner, F. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
    Meeting Abstract

    Andre, F.; Hamilton, E. P.; Loi, S.; Anders, C. K.; Schmid, P.; Stroyakovskiy, D.; Villanueva, R.; Pedrini, J. L.; Doval, D. C.; Zurawski, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Epcoritamab with rituximab + lenalidomide (R(2)) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7
    Meeting Abstract

    Lori, L. A.; Falchi, L.; Vermaat, J. S. P.; Musuraca, G.; Belada, D.; Nijland, M.; Christensen, J. H.; Offner, F.; Hoehn, D.; Marek, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study
    Meeting Abstract

    Lue, J. K.; Morschhauser, F.; Tilly, H.; Lenz, G.; Jardin, F.; Herrera, A. F.; Sharman, J. P.; Flowers, C.; Friedberg, J. W.; Trneny, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • ETHAN: A phase II study comparing different endocrine therapies for male breast cancer
    Meeting Abstract

    Leone, J. P.; Ruddy, K. J.; Rashid, N.; Giordano, S. H.; Gupta, G. P.; Hilsenbeck, S. G.; Gucalp, A.; Walsh, E. M.; Sukumar, J. S.; Makhlin, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial
    Meeting Abstract

    Li, B. T.; Clarke, J. M.; Felip, E.; Ruffinelli, J. C.; Garrido, P.; Zugazagoitia, J.; Goldberg, S. B.; Ramalingam, S. S.; Victoria, I.; Puri, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin
    Meeting Abstract

    Jaimes, Y.; LoRusso, P.; Sturm, G.; Gounder, M. M.; Yamamoto, N.; Somaiah, N.; Lugowska, I. A.; Moreno, V.; Peltzer, A.; Teufel, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Cancer burden across South Asia in 2020: A global cancer observatory analysis
    Meeting Abstract

    Jain, U.; Rahim, F.; Jain, B.; Arkalgud, A.; Sabat, C.; Hammond, A.; Tshering, P.; Patel, T. A.; Sirohi, B.; Jain, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save